Last reviewed · How we verify
TLC599 HD group — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TLC599 HD group (TLC599 HD group) — Taiwan Liposome Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TLC599 HD group TARGET | TLC599 HD group | Taiwan Liposome Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TLC599 HD group CI watch — RSS
- TLC599 HD group CI watch — Atom
- TLC599 HD group CI watch — JSON
- TLC599 HD group alone — RSS
Cite this brief
Drug Landscape (2026). TLC599 HD group — Competitive Intelligence Brief. https://druglandscape.com/ci/tlc599-hd-group. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing